Skip to main content

Main menu

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • RESOURCES
    • About BJGP
    • Conference
    • Advertising
    • BJGP Life
    • eLetters
    • Librarian information
    • Alerts
    • Resilience
    • Video
    • Audio
    • COVID-19 Clinical Solutions
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers
    • RCGP e-Portfolio

User menu

  • Subscriptions
  • Alerts
  • Log in

Search

  • Advanced search
British Journal of General Practice
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers
    • RCGP e-Portfolio
  • Subscriptions
  • Alerts
  • Log in
  • Follow bjgp on Twitter
  • Visit bjgp on Facebook
  • Blog
  • Listen to BJGP podcast
Advertisement
British Journal of General Practice

Advanced Search

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • RESOURCES
    • About BJGP
    • Conference
    • Advertising
    • BJGP Life
    • eLetters
    • Librarian information
    • Alerts
    • Resilience
    • Video
    • Audio
    • COVID-19 Clinical Solutions
Editorials

Changing beta-blockers in heart failure: when is a class not a class?

Jeffrey K Aronson
British Journal of General Practice 2008; 58 (551): 387-389. DOI: https://doi.org/10.3399/bjgp08X299317
Jeffrey K Aronson
Department of Primary Health Care, University of Oxford
Roles: Reader in Clinical Pharmacology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info
  • eLetters
  • PDF
Loading

Are all the drugs in a class the same? Take the COX-2 inhibitors, for example. Rofecoxib increases the risk of a heart attack or stroke; but do other COX-2 inhibitors, such as celecoxib, do likewise? In other words, is this adverse effect of rofecoxib a class effect? The concept of grouping compounds in classes is useful, because it prompts questions regarding their similarities and differences. But what makes a class?

The short answer is that drug class is best defined by the most important attribute of a drug: its main pharmacological target of action. Because the target is so important, the terms ‘on-target’ and ‘off-target’, originally invented in the context of drug discovery, are sometimes used to differentiate drug actions. However, in colloquial parlance not all drug classes are named according to their target, even in the World Health Organization's Anatomical Therapeutic and Chemical (ATC) drug classification system1 (Table 1). The idea of a class of drugs, even when it is based on the pharmacological target, is one that does not always bear close scrutiny, for several reasons.

View this table:
  • In this window
  • In a new window
Table 1

Origins of the colloquial names of some classes of drugs.

Firstly, the main pharmacological target may not be known. Secondly, some classes of drugs, such as monoclonal antibodies, have no common target, although they may have some effects in common, such as adverse effects. Thirdly, some drugs have more than one main target: spironolactone, for example, is an antagonist at aldosterone receptors through its active metabolite canrenone, which is why it is a potassium-sparing …

View Full Text
Back to top
Previous ArticleNext Article

In this issue

British Journal of General Practice: 58 (551)
British Journal of General Practice
Vol. 58, Issue 551
June 2008
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Or,
sign in or create an account with your email address
Email Article

Thank you for recommending British Journal of General Practice.

NOTE: We only request your email address so that the person to whom you are recommending the page knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Changing beta-blockers in heart failure: when is a class not a class?
(Your Name) has forwarded a page to you from British Journal of General Practice
(Your Name) thought you would like to see this page from British Journal of General Practice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Changing beta-blockers in heart failure: when is a class not a class?
Jeffrey K Aronson
British Journal of General Practice 2008; 58 (551): 387-389. DOI: 10.3399/bjgp08X299317

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Changing beta-blockers in heart failure: when is a class not a class?
Jeffrey K Aronson
British Journal of General Practice 2008; 58 (551): 387-389. DOI: 10.3399/bjgp08X299317
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Mendeley logo Mendeley

Jump to section

  • Top
  • Article
    • LIPOPHILICITY
    • CARDIOSELECTIVITY
    • PARTIAL AGONIST ACTIVITY
    • MEMBRANE-STABILIZING ACTIVITY
    • VASODILATATION
    • CONCLUSION
    • Notes
    • REFERENCES
  • Figures & Data
  • Info
  • eLetters
  • PDF

More in this TOC Section

  • Stroke: time to address cognition
  • Was enough, and is enough, being done to protect the primary care workforce from COVID-19?
  • Primary care networks: are they fit for the future?
Show more Editorials

Related Articles

Cited By...

Advertisement

BJGP Life

BJGP Open

 

@BJGPjournal's Likes on Twitter

 
 

British Journal of General Practice

NAVIGATE

  • Home
  • Current Issue
  • All Issues
  • Online First
  • Authors & reviewers

RCGP

  • BJGP for RCGP members
  • BJGP Open
  • RCGP eLearning
  • InnovAiT Journal
  • Jobs and careers
  • RCGP e-Portfolio

MY ACCOUNT

  • RCGP members' login
  • Subscriber login
  • Activate subscription
  • Terms and conditions

NEWS AND UPDATES

  • About BJGP
  • Alerts
  • RSS feeds
  • Facebook
  • Twitter

AUTHORS & REVIEWERS

  • Submit an article
  • Writing for BJGP: research
  • Writing for BJGP: other sections
  • BJGP editorial process & policies
  • BJGP ethical guidelines
  • Peer review for BJGP

CUSTOMER SERVICES

  • Advertising
  • Contact subscription agent
  • Copyright
  • Librarian information

CONTRIBUTE

  • BJGP Life
  • eLetters
  • Feedback

CONTACT US

BJGP Journal Office
RCGP
30 Euston Square
London NW1 2FB
Tel: +44 (0)20 3188 7679
Email: journal@rcgp.org.uk

British Journal of General Practice is an editorially-independent publication of the Royal College of General Practitioners
© 2021 British Journal of General Practice

Print ISSN: 0960-1643
Online ISSN: 1478-5242